Compare AstraZeneca plc (AZN) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs LYFT Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while LYFT Inc trades at $16.56 (market cap $6.64B). The key difference: AstraZeneca plc is far larger — about 37.4× LYFT Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.
| AZN | LYFT | |
|---|---|---|
Market Cap | $248.14B | $6.64B |
Sector | Health | Industrials |
52-Week High | $209.48 | $24.57 |
52-Week Low | $147.06 | $12.65 |
Enterprise Value | $275.41B | $6.11B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Lyft trades at $16.42, down 4.87% today, with a bullish technical outlook from moving averages but bearish oscillators. The company reported Q2 2026 revenue growth of 16.1% to a record $5.5 billion in gross bookings, though EPS missed estimates. Strong cash flow generation and expanding global rider base support fundamentals, while valuation ratios like P/E of 2.55 appear attractive relative to historical norms.
Lyft's outlook is mixed: robust revenue growth and cash flow provide upside potential, but earnings misses and competitive pressures from Uber pose risks. The stock offers value with a consensus price target of $19.17, representing 17% upside, though investors face headwinds from rising expenses and market share battles in the ride-hailing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
